5 Questions on Ovarian Cancer

Article

What is the effect of statin use on overall survival in elderly patients with platinum-resistant ovarian cancer? Do you know the cumulative ovarian cancer risk to age 80 years for BRCA1 and BRCA2 mutation carriers? Test your knowledge of ovarian cancer in our latest quiz.

What is the effect of statin use on overall survival in elderly patients with platinum-resistant ovarian cancer? Do you know the cumulative ovarian cancer risk to age 80 years for BRCA1 and BRCA2 mutation carriers? Test your knowledge of ovarian cancer in our latest quiz.

Question 1

Answer and Question 2 on Next Page »

Answer

C.

History of ovarian cancer in a first-degree relative

Those at the highest risk are patients with two or more first-degree relatives with ovarian cancer. According to the National Cancer Institute’s treatment guide on ovarian cancer, “approximately 20% of ovarian cancers are familial, and although most of these are linked to mutations in either the BRCA1 or BRCA2 gene, several other genes have been implicated.”

Question 2

Answer and Question 3 on Next Page »

Answer

B.

44%; 17%

The study reported that the cumulative breast cancer risk to age 80 years was 72% for BRCA1 carriers and 69% for BRCA2 carriers.

Question 3

Answer and Question 4 on Next Page »

Answer

D.

Patients who previously tolerated chemotherapy were less likely to accept its side effects

Those who previously tolerated chemotherapy were actually more likely to be accepting of its side effects, according to the study. The authors noted that overall, these findings “highlight the importance of communication with patients regarding prognosis, adverse effects, and symptom management to help negotiate the decision-making process.”

Question 4

Answer and Question 5 on Next Page »

Answer

B.

Abdominal/ gastrointestinal symptoms and physical function

According to the authors of the study: “This additional prognostic information could improve trial stratification, patient-doctor communication about prognosis, and clinical decision-making.”

Question 5

Answer on Next Page »

Answer

B.

Low-intensity statin use

“When statin treatment was categorized by lipophilicity and intensity, a significant survival benefit was limited to lipophilic statin users and those who took statins of moderate intensity,” the article states. Improved overall survival was observed in those with both serous and nonserous histologies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Related Content